PER 34.1% 8.9¢ percheron therapeutics limited

News: ANP Antisense Therapeutics says FDA lifts hold for multiple sclerosis drug study, page-20

  1. 4,695 Posts.
    lightbulb Created with Sketch. 720
    It's not a "bad" announcement, IF ANP had a "cleaner historical profile" with investors, it would actually be considered rather good news indeed - of course, viewing it from the perspective, as a positive or a negative the reality is, it's the start of a longer-term journey. But not a "bad" announcement....there is now a real corporate heartbeat.....at least!

    Certainly the RNAi space is truly hotting up, so this may yet emerge as a still interesting situation.......
    Last edited by Moreforme: 02/10/17
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.